CTKB Cytek Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTKB

Price (delayed)

$6.22

Market cap

$813.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$657.22M

Highlights
The debt has contracted by 24% YoY and by 6% from the previous quarter
The company's revenue rose by 18% YoY and by 5% QoQ
The quick ratio has contracted by 29% YoY and by 3.1% from the previous quarter
Cytek Biosciences's equity has decreased by 8% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.cytekdev.com/
Peers: OBIO OM

Key stats

What are the main financial stats of CTKB
Market
Shares outstanding
130.82M
Market cap
$813.73M
Enterprise value
$657.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.14
Price to sales (P/S)
4.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.41
Earnings
Revenue
$193.02M
EBIT
-$13.64M
EBITDA
-$4.41M
Free cash flow
$454,000
Per share
EPS
-$0.09
Free cash flow per share
$0
Book value per share
$2.9
Revenue per share
$1.43
TBVPS
$3.36
Balance sheet
Total assets
$494.46M
Total liabilities
$101.39M
Debt
$11.13M
Equity
$393.06M
Working capital
$335.83M
Liquidity
Debt to equity
0.03
Current ratio
6.97
Quick ratio
5.67
Net debt/EBITDA
35.5
Margins
EBITDA margin
-2.3%
Gross margin
56.7%
Net margin
-6.3%
Operating margin
-14.4%
Efficiency
Return on assets
-2.4%
Return on equity
-2.9%
Return on invested capital
-4.8%
Return on capital employed
-3.1%
Return on sales
-7.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTKB stock price

How has the Cytek Biosciences stock price performed over time
Intraday
0.32%
1 week
7.99%
1 month
-5.18%
1 year
-47.64%
YTD
-31.8%
QTD
-7.3%

Financial performance

How have Cytek Biosciences's revenue and profit performed over time
Revenue
$193.02M
Gross profit
$109.43M
Operating income
-$27.85M
Net income
-$12.15M
Gross margin
56.7%
Net margin
-6.3%
The net margin has grown by 18% from the previous quarter
The company's revenue rose by 18% YoY and by 5% QoQ
The net income is up by 14% since the previous quarter
CTKB's gross profit is up by 8% year-on-year and by 3.5% since the previous quarter

Growth

What is Cytek Biosciences's growth rate over time

Valuation

What is Cytek Biosciences stock price valuation
P/E
N/A
P/B
2.14
P/S
4.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.41
Cytek Biosciences's EPS has increased by 10% from the previous quarter
CTKB's price to book (P/B) is 21% lower than its last 4 quarters average of 2.7
Cytek Biosciences's equity has decreased by 8% YoY and by 5% from the previous quarter
The P/S is 30% below the last 4 quarters average of 6.2
The company's revenue rose by 18% YoY and by 5% QoQ

Efficiency

How efficient is Cytek Biosciences business performance
Cytek Biosciences's return on equity has increased by 12% QoQ
Cytek Biosciences's return on assets has increased by 11% QoQ
The return on invested capital is up by 6% since the previous quarter
Cytek Biosciences's ROS has increased by 4.1% from the previous quarter

Dividends

What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTKB.

Financial health

How did Cytek Biosciences financials performed over time
The quick ratio has contracted by 29% YoY and by 3.1% from the previous quarter
CTKB's current ratio is down by 25% year-on-year and by 3.2% since the previous quarter
The debt is 97% less than the equity
The debt has contracted by 24% YoY and by 6% from the previous quarter
Cytek Biosciences's equity has decreased by 8% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.